Publication details

Konkomitantní chemoradioterapie a cílená biologická léčba u glioblastoma multiforme

Title in English Concomitant Chemoradiotherapy and Targeted Therapy in Glioblastoma Multiforme
Authors

BURKOŇ Petr LAKOMÝ Radek BURKOŇOVÁ D. FADRUS Pavel

Year of publication 2010
Type Article in Periodical
Magazine / Source Česká a slovenská neurologie a neurochirurgie
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords glioblastoma multiforme; chemotherapy; biomarkers; angiogenesis
Description Glioblastoma multiforme (GBM) is among the most aggressive of malignant brain tumors and therapeutic options for it are limited. Standard therapy is maximal surgical resection and adjuvant concurrent chemoradiotherapy and maintenance therapy with temozolomid. This approach improves median and 5-year survival in comparison with postsurgical radiotherapy alone. MGMT (O6-Methylguanine-DNA-methyltransferase) promoter methylation is the first predictive biomarker. Low levels of expression of MGMT protein are correlated with successful treatment. Additional predictive and prognostic biomarkers are required, especially in the light of the development of targeted therapy – antibodies and tyrosine kinase inhibitors. New therapeutic approaches are under intensive investigation. The most promising data currently derive from anti-angiogenic therapies, such as bevacizumab and cediranib. This review presents a summary covering chemotherapy, the significance of promoter methylation MGMT, pseudoprogression and the possible role of targeted therapy in the treatment of glioblastoma multiforme.

You are running an old browser version. We recommend updating your browser to its latest version.

More info